What Is 3-Methylglutaconic aciduria type 4

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Methylglutaconic aciduria type 4 (MGA4) is a rare genetic disorder caused by mutations in the DNAJC19 gene, inherited in an autosomal recessive pattern. It is characterized by elevated levels of 3-methylglutaconic acid in urine, cardiomyopathy, growth delays, and neurological symptoms, with onset typically in infancy.

Key Facts

3-Methylglutaconic aciduria type 4 is caused by mutations in the DNAJC19 gene on chromosome 3.
It follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutation.
The condition is most prevalent among individuals of French-Canadian or Libyan-Jewish descent.
Symptoms often appear in infancy, including hypertrophic cardiomyopathy and developmental delays.
Diagnosis is confirmed through urine organic acid analysis and genetic testing for DNAJC19 mutations.

Overview

3-Methylglutaconic aciduria type 4 (MGA4) is a rare inherited metabolic disorder that disrupts mitochondrial function and leads to the abnormal buildup of 3-methylglutaconic acid in bodily fluids. It is part of a group of five types of 3-methylglutaconic acidurias, each linked to different genetic mutations and clinical features, with type 4 being among the most severe.

Primarily affecting infants, MGA4 presents with multisystem complications, including cardiac, neurological, and developmental issues. Early diagnosis is crucial due to the progressive nature of symptoms, which can lead to life-threatening heart conditions if untreated.

Elevated 3-methylglutaconic acid in urine is a hallmark biochemical marker used to screen for the disorder during metabolic testing.
The condition is caused by mutations in the DNAJC19 gene on chromosome 3q26.33, which encodes a mitochondrial protein involved in protein import and stability.
Autosomal recessive inheritance means both parents must carry one mutated copy of the gene for a child to be affected, with a 25% recurrence risk per pregnancy.
Populations with higher carrier frequencies include French-Canadian communities in Quebec and Libyan-Jewish families, where founder mutations have been identified.
Clinical features often include neonatal-onset lactic acidosis, microcephaly, delayed development, and progressive cardiomyopathy, particularly dilated or hypertrophic forms.

How It Works

The DNAJC19 gene plays a critical role in mitochondrial function, particularly in the inner membrane where it assists in protein folding and quality control. Mutations impair mitochondrial dynamics, leading to energy deficits in high-demand organs like the heart and brain.

DNAJC19 protein: This co-chaperone protein helps regulate the mitochondrial import of proteins; its dysfunction leads to impaired oxidative phosphorylation and increased cell death.
Mitochondrial dysfunction: Disrupted energy production results in elevated lactate levels and cellular stress, particularly in cardiac and neural tissues.
3-Methylglutaconic acid accumulation: Due to inefficient metabolism of leucine, this organic acid builds up and is excreted in urine, serving as a diagnostic clue.
Cardiomyopathy mechanism: Impaired mitochondrial function in cardiomyocytes leads to hypertrophy and reduced contractility, often presenting within the first year of life.
Neurological impact: Mitochondrial failure in neurons contributes to developmental delays, hypotonia, and microcephaly observed in affected children.
Endocrine abnormalities: Some patients develop short stature and growth hormone deficiency, possibly linked to chronic energy deficits during development.

Comparison at a Glance

Below is a comparison of 3-methylglutaconic aciduria types 1 through 5 based on genetic cause, inheritance, and key clinical features:

Type	Gene	Inheritance	Primary Features	Onset
Type 1	AUH	Autosomal recessive	Mild neurological symptoms, no major organ involvement	Childhood
Type 2 (Barth syndrome)	TAZ	X-linked	Cardiomyopathy, neutropenia, muscle weakness	Infancy (males)
Type 3 (Costeff syndrome)	OPA3	Autosomal recessive	Optic atrophy, movement disorders	Childhood
Type 4 (MGA4)	DNAJC19	Autosomal recessive	Severe cardiomyopathy, lactic acidosis, developmental delay	Neonatal/Infancy
Type 5	TAZ (de novo)	Autosomal recessive	Similar to type 4 but rarer, less documented	Infancy

While all types involve elevated 3-methylglutaconic acid, type 4 stands out due to its severe cardiac presentation and association with specific ethnic populations. Unlike Barth syndrome (type 2), which primarily affects males due to X-linkage, MGA4 affects both sexes equally and often leads to early mortality without intervention.

Why It Matters

Understanding 3-Methylglutaconic aciduria type 4 is essential for early diagnosis, genetic counseling, and managing life-threatening complications. Given its rarity and overlapping symptoms with other metabolic disorders, awareness among pediatricians and geneticists is critical.

Early screening in at-risk populations can lead to timely diagnosis through urine organic acid analysis and targeted DNA testing.
Cardiac monitoring is vital; regular echocardiograms help detect cardiomyopathy before symptoms become severe.
Genetic counseling is recommended for carriers, especially in high-prevalence communities, to assess reproductive risks.
Supportive treatment includes heart failure medications, physical therapy, and nutritional support, though no cure currently exists.
Research into gene therapy and mitochondrial-targeted drugs offers future hope for modifying disease progression.
Improved newborn screening protocols may help identify MGA4 earlier, potentially improving long-term outcomes through proactive care.

As research advances, understanding the role of DNAJC19 in mitochondrial health may also shed light on broader neurological and cardiac diseases, making MGA4 a significant focus in metabolic genetics.